Although diversification can sometimes be a strength, it can also prove to be a double-edged sword in the long run. Here’s how.
What are the three key reasons why J&J could be a top performer in the future?
In the final part of a three-part series, I take a deep dive into J&J's pharmaceuticals segment and ask whether it's as attractive as many investors believe.
In the second of a three-part series I take a closer look at J&J's (NYSE: JNJ) consumer segment to find out if it could make the stock take off.
In the first of a three-part series, I put Johnson & Johnson's medical devices and diagnostics segment under the investment microscope.
Philip Morris could be a strong performer in future. Here's why.
Novartis has changed to a new strategy. Is it likely to be a successful one?
With shares disappointing in recent years, is Procter & Gamble now attractive?
Shares in GlaxoSmithKline have underperformed the index in recent years. Does this mean the stock is undervalued?
Having had a strong performance in recent years, does Bristol-Myers Squibb still offer good value for your money at current price levels?
After tracking the index for five years, Pfizer could be worth buying. Here's why.
After an impressive share price performance since it listed, is AbbVie still worth buying?
Is the relative stability provided by Johnson & Johnson's diversified business model a major advantage when compared to Pfizer and Bristol-Myers Squibb?
Despite some disappointing news, Eli Lilly's stock has made a strong start to 2014. Can it keep going?
Shares in Bristol-Myers Squibb performed relatively positively last week. Can they keep it going?
After a strong recent run, are shares in Merck (NYSE: MRK) still worth buying?
Shares in Merck have made a strong start to 2014. Can they keep going?
After an awesome 2013, Celgene (NASDAQ: CELG) has made a bad start to the year. Can it recover?
The year 2013 was a great one for Bristol-Myers Squibb (NYSE: BMY); 2014 could also be a strong year due to a potential catalyst.
Despite mixed recent news flow, Roche remains a company with significant potential.